Bassem Elmankabadi, M.D., Executive Medical Director, Clinical Development at FibroGen, will present the Phase II Study results from the Pamrevlumab 079 trial (Mission Study) in patients with non-ambulatory Duchenne muscular dystrophy on Friday, 6/25 at 7:47 PM ET.
